



Paediatric Diseases Working Party


Chair: **Krzysztof Kalwak** | Secretary: **Katharina Kleinschmidt** |
Clinical Trial Committee Chair: **Marc Ansari**

Study coordinator: **Arnaud Dalissier** | Data Manager: **Aleksandra Gavrilina** |
Statisticians: **Jacques-Emmanuel Galimard, Mouad Abouqateb**

Publication 2025

- Di Nardo et al. **International expert consensus statement on PICU admission and early critical care management for paediatric patients following haematopoietic cell transplant and immune effector cell therapy.** Lancet Child Adolesc Health. 2025 Jun.
- Buchbinder N & Michel V et al. **Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party.** Br J Haematol. 2025.
- Di Majo BE et al. **A. Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWP.** Bone Marrow Transplant. 2025 Dec.
- Bertaina A et al. **Interplay between acute graft-versus-host disease and graft-versus-leukemia effect in pediatric acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: implications for relapse incidence and survival.** Bone Marrow Transplant. 2026 Feb.
- Willasch Am et al. **Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission.** Bone Marrow Transplant. 2026 Jan.
- Hammoudi T et al. **Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group.** Blood Adv. 2025 Dec 9.
- Deimundo Roura C et al. **Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group.** Transplant Cell Ther. 2025 Oct 30.
- Ramme K et al. **Late effects after hematopoietic stem cell transplantation in patients with HLH: A Histiocyte Society, PDWP, IEWP, and TCWP EBMT Study.** J Allergy Clin Immunol. 2026 Feb.
- Rettinger E et al. **Paediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation. The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia.** Leukemia. 2025 Oct.

PDWP 2025 Publications



Presentations EBMT 2026


Oral Presentations

- **Franco Locatelli**, Outcomes of pediatric patients with acute leukemias given either PTCy or TCR $\alpha\beta$ /CD19+ depleted HLA-haplo HCT
- **Katharina Kleinschmidt & Claire Horgan** Use of Letermovir after transplant
- **Meinolf Suttorp** Impact of Different Conditioning Regimens Administered for SCT in Pediatric Chronic Myeloid Leukemia (CML)
- **Kanchan Rao** GLIS2 MUTATION

Poster Presentations

- **Claire Horgan & Rob Wynn** Outcomes of children with AML relapsing within 6 months of alloHCT
- **Kirill Kirgizov** Belumosudil usage for the treatment of steroid-refractory chronic GvHD
- **B. Di Majo** Matched sibling cord blood transplants in malignant and non-malignant disorders

Registry Trends in First Allogeneic and Autologous HCT in Pediatric Patients, 2000-2024



*Restricted to major malignant indications (acute leukemia, chronic leukemia, MDS/MPN, lymphomas, solid tumors, and plasma cell disorders)

Active Studies

1. Kanchan Rao; **HSCT in patients with GLIS2+ AML**
2. Jacek Wachowiak; **Allo-HSCT for ped r-r KMT2A-r AML in CR-EBMT**
3. Monika Richert-Przygońska; **High-dose chemotherapy and hematopoietic cell transplantation in pediatric germ-cell tumors**
4. S. Giardino; **HaploHCT in Neuroblastoma**
5. E. Latos-Grażyński; **Allogeneic vs autologous HSCT in B-cell NHL**
6. T. Dietch; **Gonadal function in patients receiving pre-transplant conditioning with Busulphan or Treosulphan**
7. Giorgio Ottaviano; **HSCT in AML & ALL patients with Down Syndrome (collab with CIBMTR)**
8. Giorgio Ottaviano; **Impact of SCT for Histiocytic Sarcoma (HS) in children**

Centers interested in contributing data to these studies are invited to contact PDWP Study Coordinator: arnaud.dalissier@ebmt.org